<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="231dcf45-3b5a-4954-b49f-034bebdf2039"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use FLUOCINOLONE ACETONIDE OIL EAR DROPSÂ safely and effectively. See full prescribing information for FLUOCINOLONE ACETONIDE OIL EAR DROPS.</content>
      <br/>
      <br/>
      <content styleCode="bold">FLUOCINOLONE ACETONIDE OIL ear drops, for otic use </content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 1988</content>
   </title>
   <effectiveTime value="20250519"/>
   <setId root="a48fba5c-815f-4d82-b8e0-20665abd7b26"/>
   <versionNumber value="18"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="123797875" root="1.3.6.1.4.1.519.1"/>
            <name>Amneal Pharmaceuticals LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="963900878" root="1.3.6.1.4.1.519.1"/>
                        <name>Amneal Pharmaceuticals, LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="65162-702" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="65162-702" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="65162-702" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="65162-702" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3b1c8e95-9966-41a2-880f-d636f99ece30"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250519"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="65162-702" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Fluocinolone Acetonide</name>
                        <formCode code="C42965" displayName="OIL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Fluocinolone Acetonide</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.11"/>
                              <denominator unit="mL" value="20"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0CD5FD6S2M" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FLUOCINOLONE ACETONIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0CD5FD6S2M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FLUOCINOLONE ACETONIDE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0RE8K4LNJS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ISOPROPYL MYRISTATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="N6K5787QVP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LIGHT MINERAL OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5TL50QU0W4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PEANUT OIL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7L6R1SQ6M0" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OLETH-2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="20"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="65162-702-94" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20150922"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA091306" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20150922"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" displayName="yellow" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38192" displayName="AURICULAR (OTIC)" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_48a0e91b-f312-4b7b-8793-a4243b21b18a">
               <id root="4c027e09-5d56-432e-8a38-20f74748d70b"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Fluocinolone acetonide oil 0.01% ear drops are indicated for the topical treatment of chronic eczematous external otitis in adults and pediatric patients 2 years of age and older. </paragraph>
               </text>
               <effectiveTime value="20250519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Fluocinolone acetonide oil 0.01% ear drops is a corticosteroid indicated for the topical treatment of chronic eczematous external otitis in adults and pediatric patients 2 years of age and older. (1) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_1ac300b1-ede1-4e26-9636-5af2ec1aa9c9">
               <id root="5371b08c-2acf-4a1e-99e7-3b0e4fb10bb7"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Fluocinolone acetonide oil 0.01% ear drops are for otic administration only. Not for oral, ophthalmic, or intravaginal use. </paragraph>
                  <paragraph>Apply fluocinolone acetonide oil 0.01% ear drops into the affected ear using the supplied ear dropper. To apply, tilt head to one side so that the ear is facing up. Then gently pull the ear lobe backward and upward and apply 5 drops of fluocinolone acetonide oil 0.01% ear drops into the ear. Keep head tilted for about a minute to allow fluocinolone acetonide oil 0.01% ear drops to penetrate lower into the ear canal. Gently pat excess material dripping out of the ear using a clean cotton ball. Follow these instructions twice each day for 7 to 14 days. </paragraph>
                  <paragraph>Discontinue fluocinolone acetonide oil 0.01% ear drops when control of disease is achieved within 2 weeks, or contact the healthcare provider if no improvement is seen within 2 weeks. </paragraph>
                  <paragraph>Do not use on the face, axillae, or groin unless directed by the healthcare provider. Do not apply to intertriginous areas due to the increased risk of local adverse reactions <content styleCode="italics">[see Adverse Reactions (6)</content> and <content styleCode="italics">Use in Specific Populations (8.4)]</content>. </paragraph>
               </text>
               <effectiveTime value="20250519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Fluocinolone acetonide oil 0.01% ear drops is not for oral, ophthalmic, or intravaginal use. (2) </item>
                           <item>Apply 5 drops of fluocinolone acetonide oil 0.01% ear drops into the affected ear twice daily for 7 to 14 days. (2) </item>
                           <item>Do not use on face or intertriginous areas. (2) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_ed9cc327-a9b2-497e-8154-bd9219fd4770">
               <id root="f9ef044a-12ab-4c4d-bb9a-beda72ef21f8"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Ear drops, containing 0.01% fluocinolone acetonide supplied in bottles containing 20 mL (dropper included). </paragraph>
               </text>
               <effectiveTime value="20250519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ear drops, containing 0.01% fluocinolone acetonide, supplied in bottles containing 20 mL. (3) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_7600ad47-5a2d-4055-b6a8-9334addd62c5">
               <id root="b97f2895-b427-4be5-aeb7-c175751427b7"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None. </paragraph>
               </text>
               <effectiveTime value="20250519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (4) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_4e1684e1-bdaa-4046-ac6f-e2816f5fb48e">
               <id root="b421d034-119a-4f36-9100-f28e1b5adeee"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20250519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Endocrine System Adverse Reactions: </content>
                              <list listType="unordered" styleCode="Circle">
                                 <item>Topical corticosteroids can produce reversible hypothalamic-pituitaryÂ­adrenal (HPA) axis suppression, Cushingâs syndrome, hyperglycemia, and glucosuria. (5.1) </item>
                                 <item>Pediatric patients may be more susceptible to systemic toxicity from equivalent doses. (5.1,8.4) </item>
                                 <item>Systemic absorption may require evaluation for HPA axis suppression. Potent corticosteroids use on large areas, prolonged use or occlusive use, altered skin barrier, liver failure, and young age may increase systemic absorption. Modify use should HPA axis suppression develop. (5.1). </item>
                              </list>
                           </item>
                           <item>
                              <content styleCode="underline">Local Adverse Reactions:</content> Local adverse reactions may include atrophy, striae irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis, and may be more likely with occlusive use or more potent corticosteroids. (5.2, 6.1) </item>
                           <item>
                              <content styleCode="underline">Ophthalmic Adverse Reactions:</content> May increase the risks of glaucoma and posterior subcapsular cataract. Avoid contact of fluocinolone acetonide oil 0.01% ear drops with eyes. Advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation. (5.3) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_2108f383-95f2-4ec1-82d5-003b950b0d7e">
                     <id root="626d46e1-fdeb-462b-af1f-42a5ec03e856"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Endocrine System Adverse Reactions</title>
                     <text>
                        <paragraph>Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. Cushingâs syndrome, hyperglycemia, and glucosuria can result from systemic absorption of topical corticosteroids.</paragraph>
                        <paragraph>HPA axis suppression and Cushingâs syndrome have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and subnormal response to ACTH stimulation. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios <content styleCode="italics">[see Use in Specific Populations (8.4)]</content>. </paragraph>
                        <paragraph>Conditions which increase systemic absorption include the use of more potent corticosteroids, use over large surface areas, use over prolonged periods, use of occlusive dressings, altered skin barrier, liver failure, and young age. Use of more than one corticosteroid-containing product at the same time may increase total systemic corticosteroid exposure. Because of the potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression. The ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression. </paragraph>
                        <paragraph>If HPA axis suppression is documented, an attempt should be made to withdraw the drug to reduce the frequency of application, or to substitute a less potent corticosteroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. </paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_29e85073-3f54-4d2a-8ee7-ed3b2caf81c7">
                     <id root="13b3422f-a57c-42c7-9a40-4f8d3a2437be"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Local Adverse Reactions</title>
                     <text>
                        <paragraph>Local adverse reactions may occur with use of topical corticosteroids, including fluocinolone acetonide oil 0.01%, and may be more likely to occur with occlusive use, prolonged use, or use of higher potency corticosteroids. Some local adverse reactions may be irreversible. Reactions may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria <content styleCode="italics">[see Adverse Reactions (6.1)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0606c9d6-483d-44da-a5dd-aa1af1bc88f7">
                     <id root="840ca2a1-87eb-466b-9224-01b23c51e91a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Ophthalmic Adverse Reactions</title>
                     <text>
                        <paragraph>Use of topical corticosteroids may increase the risks of glaucoma and posterior subcapsular cataract. Glaucoma and cataracts have been reported in postmarketing experience with the use of topical corticosteroid products. Avoid contact of fluocinolone acetonide oil 0.01% with eyes. Advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation.</paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_263582bc-e57b-4042-a181-f3cf29dbc74f">
                     <id root="9da7e298-8df3-4e47-a5c0-1f9149b89283"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Allergic Contact Dermatitis</title>
                     <text>
                        <paragraph>Use of topical corticosteroids can cause allergic contact dermatitis. Allergic contact dermatitis to any component of topical corticosteroids is usually diagnosed by a failure to heal rather than a clinical exacerbation. Clinical diagnosis of allergic contact dermatitis can be confirmed by patch testing.</paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_62702dca-c6ed-4f4c-81d0-a770bacf34ae">
                     <id root="8a67ee56-48d9-46c8-acf7-70e04d456dbe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Concomitant Skin Infections</title>
                     <text>
                        <paragraph>Use of topical corticosteroids may delay healing or worsen concomitant skin infections. Treat concomitant skin infections with an appropriate antimicrobial agent. If the infection persists unchanged, discontinue fluocinolone acetonide oil 0.01% until the infection has been adequately treated.</paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_cf7acb70-43df-43bd-bd9f-a3df64b78509">
                     <id root="e96c4e88-246c-44f9-bf6a-669252ab4628"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Use in Peanut Sensitive Individuals</title>
                     <text>
                        <paragraph>Use caution in prescribing fluocinolone acetonide oil 0.01% for peanut sensitive individuals <content styleCode="italics">[see Description (l1)]</content>.</paragraph>
                        <paragraph>Should signs of hypersensitivity present (wheal and flare reactions, pruritus, or other manifestations), or should disease exacerbations occur, discontinue fluocinolone acetonide oil 0.01% immediately and institute appropriate therapy. </paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_9440e503-baf7-441c-991f-439bc85d32c3">
               <id root="ee173101-fc9a-450c-bea4-eb0e0953b18c"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are discussed in more detail in other sections of the labeling: </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Endocrine System Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (5.1), Use in Specific Populations (8.4)]</content>
                     </item>
                     <item>Local Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>
                     </item>
                     <item>Ophthalmic Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250519"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most commonly reported adverse reactions (â¥ 1%) were headache (3%), URI (2%), cough (2%), eczematous otitis (1%). (6.1) </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Amneal Pharmaceuticals LLC at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_1da2f44a-e962-4990-a468-cc3c507f516f">
                     <id root="cb92d846-b20e-4323-b89a-380d6ebc3200"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Studies Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In trials that enrolled 154 subjects (adults and pediatric subjects 2 years and older) with chronic eczematous external otitis who were treated with five drops per ear of fluocinolone acetonide oil 0.01% twice daily for a maximum 14 days of treatment, the following adverse reactions were reported: </paragraph>
                        <paragraph>
                           <content styleCode="bold">Table 1: Adverse Reactions in â¥ 1% of </content>Â <content styleCode="bold">Fluocinolone Acetonide Oil 0.01%-Treated Adult and Pediatric Subjects 2 Years of Age and Older with Chronic Eczematous External Otitis, N=154</content>
                        </paragraph>
                        <table cellspacing="0" cellpadding="0" border="1">
                           <col width="3pt1pt1pt"/>
                           <col width="140.1pt"/>
                           <tbody>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Headache </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4 (3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>URI </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Cough </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3 (2)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Eczematous otitis </paragraph>
                                 </td>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2 (1)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2b654a68-a4d2-42f0-b2de-16af1fc930ea">
                     <id root="5f7d4226-0b4a-423f-821a-34552598c4fd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of products containing topical corticosteroids. Because postmarketing adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Endocrine Disorders:</content> HPA axis suppression and Cushingâs syndrome <content styleCode="italics">[see Use in Specific Populations (8.4)] </content>
                           </item>
                           <item>
                              <content styleCode="italics">Eye Disorders:</content> glaucoma and cataracts <content styleCode="italics">[see Warnings and Precautions (5.3)] </content>
                           </item>
                           <item>
                              <content styleCode="italics">Nervous System Disorders:</content> intracranial hypertension including bulging fontanelles, headaches, and bilateral papilledema <content styleCode="italics">[see Use in Specific Populations (8.4)] </content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d8fb27d1-edc0-46b8-9cc1-d87f6735066d">
               <id root="d3d5ee7a-5b3a-43c8-9141-e1bf8cad6959"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <br/>
               </text>
               <effectiveTime value="20250519"/>
               <component>
                  <section ID="LINK_c7ddff79-330d-427b-b47b-400ef0464579">
                     <id root="e8538b49-94c7-40c3-b994-8a2bb95fc944"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Available data from case reports, case series, and observational studies on fluocinolone acetonide use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Observational studies suggest maternal use of high to super-high potency topical steroids may be associated with an increased risk of low birthweight infants. Advise pregnant women to use fluocinolone acetonide oil 0.01% on the smallest area of skin and for the shortest duration possible. </paragraph>
                        <paragraph>Corticosteroids can cause fetal malformations in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids cause fetal malformations after dermal application in laboratory animals. </paragraph>
                        <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b6a0645b-75e0-4d44-80e3-18b6b0e91f71">
                     <id root="2cb0f8d1-ce15-425a-bdfe-6d4334080463"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There is no information regarding the presence of fluocinolone acetonide in breast milk or its effects on the breastfed infant or on milk production. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. The developmental and health benefits of breastfeeding should be considered along with the motherâs clinical need for fluocinolone acetonide oil 0.01% and any potential adverse effects on the breastfed infant from fluocinolone acetonide oil 0.01% or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2a76746e-04aa-4ca6-8470-1aa0e68d79ac">
                     <id root="de3a63c6-5bd2-43e7-9909-3fd7757ec58a"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of fluocinolone acetonide oil 0.01% for the topical treatment of chronic eczematous external otitis have been established in pediatric patients aged 2 years and older.</paragraph>
                        <paragraph>Safety and effectiveness of fluocinolone acetonide oil 0.01% in pediatric patients with chronic eczematous external otitis below the age of 2 years have not been established.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Systemic Adverse Reactions in Pediatric Patients</content>
                        </paragraph>
                        <paragraph>HPA Axis suppression, Cushingâs syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and subnormal response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk for systemic adverse reactions than are adults when treated with topical corticosteroids <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Evaluation in Peanut-Sensitive Pediatric Patients</content>
                        </paragraph>
                        <paragraph>A clinical trial was conducted to assess the safety of the formulation of fluocinolone acetonide oil 0.01%, which contains refined peanut oil, in patients with known peanut allergies. The trial enrolled 13 pediatric subjects with atopic dermatitis, 6 to 17 years of age. Fluocinolone acetonide oil 0.01% is not approved for the treatment of atopic dermatitis. Of the 13 subjects, 9 were Radioallergosorbent Test (RAST) positive to peanuts and 4 had no peanut sensitivity (controls). The trial evaluated the subjectsâ responses to both prick test and patch test utilizing refined peanut oil, the formulation of fluocinolone acetonide oil 0.01% and histamine/saline controls. Subjects were also treated with the formulation of fluocinolone acetonide oil 0.01% twice daily for 7 days. Prick test and patch test results for all 13 subjects were negative to the formulation of fluocinolone acetonide oil 0.01% and the refined peanut oil. One of the 9 peanut-sensitive subjects experienced an exacerbation of atopic dermatitis after 5 days of use on the formulation of fluocinolone acetonide oil 0.01%.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Evaluation in Pediatric Patients 2 to 6 years old</content>
                        </paragraph>
                        <paragraph>Use of the formulation of fluocinolone acetonide oil 0.01% in pediatric patients 2 to 6 years old is supported by open-label safety trials conducted in 33 pediatric subjects (20 subjects ages 2 to 6 years, 13 subjects ages 7 to 12 years) with moderate to severe stable atopic dermatitis. Baseline body surface area involvement was 50% to 75% in 15 subjects and greater than 75% in 18 subjects. Subjects were treated with the formulation of fluocinolone acetonide oil 0.01% twice daily for 4 weeks. Morning preÂ­stimulation cortisol and post-ACTH stimulation cortisol levels were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. At the end of treatment, 4 out of 18 subjects aged 2 to 5 years showed low preÂ­stimulation cortisol levels (3.2 to 6.6 mcg/dL; normal: cortisol &gt; 7 mcg/dL) but all had normal responses to 0.25 mg of ACTH stimulation (cortisol &gt; 18 mcg/dL) <content styleCode="italics">[see Clinical Pharmacology (12.2)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_94dfdaa6-3893-42c2-9260-ca4a11462f2f">
               <id root="76c0281e-4634-4390-8327-f3145c9ffa27"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Fluocinolone acetonide oil 0.01% ear drops contain fluocinolone acetonide [(6a, 11b, 16a)-6,9-difluoroÂ­11,21-dihydroxy-16, 17[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene3,20-dione, cyclic 16,17 acetal with acetone], a synthetic corticosteroid for topical dermatologic use. Chemically, fluocinolone acetonide is C<sub>24</sub>H<sub>30</sub>F<sub>2</sub>O<sub>6</sub>. It has the following structural formula: </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Fluocinolone acetonide has a molecular weight of 452.50. It is a white crystalline powder that is odorless, stable in light, and melts at 270Â°C with decomposition; soluble in alcohol, acetone and methanol; slightly soluble in chloroform; insoluble in water. </paragraph>
                  <paragraph>Each gram of fluocinolone acetonide oil 0.01% contains approximately 0.11 mg of fluocinolone acetonide in a blend of oils, which contains isopropyl alcohol, isopropyl myristate, light mineral oil, oleth-2, and refined peanut oil NF. </paragraph>
                  <paragraph>Fluocinolone acetonide oil 0.01% is formulated with 48% refined peanut oil. The bulk refined peanut oil, used in fluocinolone acetonide oil 0.01% is heated at 246Â°C (475Â°F) for at least 15 minutes. The refined peanut oil used in fluocinolone acetonide oil 0.01% is routinely tested for peanut proteins through amino acid analysis; the quantity of amino acids is below 0.5 parts per million (ppm). </paragraph>
               </text>
               <effectiveTime value="20250519"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>structural formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fluocinolone-acetonide-0-01-percent-topical-oil-ea-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_bccb04cc-3991-4ea2-b6f4-04a6afd0b8f3">
               <id root="1bb58b65-23bb-4df4-9ea8-c5106c11a17a"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250519"/>
               <component>
                  <section ID="LINK_f1abae1d-7871-43d7-bbb1-77ffe4b1ffb5">
                     <id root="cd6a30f2-7ec4-4080-8f47-3a67df32cbe2"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in eczematous external otitis is unknown. </paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_341097fb-f403-4324-b506-0e5f01fc8f3a">
                     <id root="2edc9937-eccd-4a79-9e93-e615a8bc26a4"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Vasoconstrictor Assay</content>
                        </paragraph>
                        <paragraph>Fluocinolone acetonide oil 0.01% is in the low to medium range of potency as compared with other topical corticosteroids in vasoconstrictor studies. However, similar blanching scores do not necessarily imply therapeutic equivalence. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Hypothalamic-Pituitary-Adrenal (HPA) Axis Suppression </content>
                        </paragraph>
                        <paragraph>HPA axis suppression was evaluated in 33 pediatric subjects 2 to 12 years old (20 subjects ages 2 to 6 years, 13 subjects ages 7 to 12 years) with moderate to severe stable atopic dermatitis. Subjects were treated with the formulation of fluocinolone acetonide oil 0.01% twice daily for 4 weeks. Baseline body surface area involvement was 50% to 75% in 15 subjects and greater than 75% in 18 subjects. Morning pre-stimulation cortisol and post-ACTH stimulation cortisol levels were obtained in each subject at the beginning of the trial and at the end of 4 weeks of treatment. At the end of treatment, 4 out of 18 subjects aged 2 to 5 years showed low pre-stimulation cortisol levels (3.2 to 6.6 mcg/dL; normal cortisol &gt;7 mcg/dL) but all had normal responses to 0.25 mg of ACTH stimulation (cortisol &gt; 18 mcg/dL) <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_40da22ab-9880-419c-aac4-3222230c217b">
                     <id root="2fc00ff1-fad4-4dc9-906f-1b25cc97e452"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Topical corticosteroids can be absorbed from intact healthy skin. The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the product formulation and the integrity of the epidermal barrier. Occlusion, inflammation and/or other disease processes in the skin may increase percutaneous absorption. The use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids may be necessary due to the fact that circulating levels are often below the level of detection. Once absorbed through the skin, topical corticosteroids are metabolized, primarily in the liver, and are then excreted by the kidneys. Some corticosteroids and their metabolites are also excreted in the bile. </paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5daa79e6-a212-4003-bec5-c4661f04ac51">
               <id root="ab87524c-aef3-4dce-a7bd-389839cc1f04"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250519"/>
               <component>
                  <section ID="LINK_de7b6a6c-102a-443a-8563-e9fb72cae2d9">
                     <id root="0b2e0f73-65c5-4fc4-ade9-8d136c5410cd"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No carcinogenicity, genotoxicity, or fertility studies were conducted with fluocinolone acetonide oil 0.01%. However, some corticosteroids are genotoxic in various genotoxicity tests (i.e., the <content styleCode="italics">in vitro</content> human peripheral blood lymphocyte chromosome aberration assay with metabolic activation, the <content styleCode="italics">in vivo</content> mouse bone marrow micronucleus assay, the Chinese hamster micronucleus test and the <content styleCode="italics">in vitro</content> mouse lymphoma gene mutation assay). </paragraph>
                     </text>
                     <effectiveTime value="20250519"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_995374a6-9348-42d8-aeae-912d8e71b14b">
               <id root="ce5025ba-3b73-41d9-898d-196a1146cddf"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>In two vehicle-controlled trials (Trial 1 and Trial 2), 154 subjects (adults and pediatric subjects 2 years of age and older) with chronic eczematous external otitis were treated with 5 drops per ear of fluocinolone acetonide oil 0.01% twice daily for 7 days. Efficacy was assessed on Day 7 by clearance of the signs and symptoms of eczematous external otitis, and the results are presented in the following table: </paragraph>
                  <paragraph>
                     <content styleCode="bold">Table 2: Efficacy Results at Day 7 in Subjects with Chronic Eczematous External Otitis in Trial 1 and 2*</content>
                  </paragraph>
                  <table cellspacing="0" cellpadding="0" border="1">
                     <col width="3pt1pt1pt"/>
                     <col width="1.75in"/>
                     <col width="126.05pt"/>
                     <tbody>
                        <tr>
                           <td/>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Fluocinolone Acetonide Oil 0.01% </content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Vehicle</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Study 1 </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>30% </paragraph>
                              <paragraph>(14/47)</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>7% </paragraph>
                              <paragraph>(3/46)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Study 2 </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>32% </paragraph>
                              <paragraph>(9/28)</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>3% </paragraph>
                              <paragraph>(1/30)</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>* Erythema, scaling, pruritus, erosion/oozing/crusting and debris </paragraph>
               </text>
               <effectiveTime value="20250519"/>
            </section>
         </component>
         <component>
            <section ID="LINK_a0b45d85-af35-4ea1-b85b-0827eb4c813b">
               <id root="7f6ae5ff-1cf2-43d9-b885-238ea434079d"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED</title>
               <text>
                  <paragraph>Fluocinolone acetonide oil 0.01% ear drops are supplied in 1 fluid ounce bottles with a net contents of 20 mL, (dropper included) (NDC # 65162-702-94). </paragraph>
                  <paragraph>Storage: Keep tightly closed. Store at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted between 15Â° to 30Â°C (59Â° to 86Â°F) [see USP Controlled Room Temperature]. </paragraph>
                  <paragraph>Discard fluocinolone acetonide oil 0.01% ear drops 2 months after initial use. </paragraph>
               </text>
               <effectiveTime value="20250519"/>
            </section>
         </component>
         <component>
            <section ID="LINK_7f1499bb-6eb0-433e-ad99-1e4cdeab02da">
               <id root="b1cc66d2-c3ea-4b39-98df-4088514e2b1b"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Administration Instructions </content>
                  </paragraph>
                  <paragraph>Advise patients that fluocinolone acetonide oil 0.01% is for otic administration only and not for oral, ophthalmic, or intravaginal use <content styleCode="italics">[see Dosage and Administration (2)]</content>. </paragraph>
                  <paragraph>Advise patients to avoid use of fluocinolone acetonide oil 0.01% on the face, axillae, or groin unless directed by their healthcare provider <content styleCode="italics">[see Dosage and Administration (2)]</content>. </paragraph>
                  <paragraph>Advise patients to discontinue therapy when control of disease is achieved. Instruct patients to contact their healthcare provider if no improvement is seen within 2 weeks <content styleCode="italics">[see Dosage and Administration (2)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Endocrine System Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Instruct patients not to use other corticosteroid-containing products while using fluocinolone acetonide oil 0.01% without first consulting their healthcare provider <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Ophthalmic Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Advise patients to avoid contact with the eyes and in case of contact, wash eyes liberally with water. Instruct patients to tell their healthcare provider if they develop any visual symptoms <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Pregnancy and Lactation</content>
                  </paragraph>
                  <paragraph>Advise patients to use fluocinolone acetonide oil 0.01% on the smallest area of skin and for the shortest duration possible while pregnant or breastfeeding. Advise patients that are breastfeeding not to apply fluocinolone acetonide oil 0.01% directly to the nipple and areola to avoid direct infant exposure <content styleCode="italics">[See Use in Specific Populations (8.1 and 8.2)]</content>. </paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Amneal Pharmaceuticals</content>
                  </paragraph>
                  <paragraph>Bridgewater, NJÂ  08807</paragraph>
                  <paragraph>Rev. 05-2025-01</paragraph>
               </text>
               <effectiveTime value="20250519"/>
            </section>
         </component>
         <component>
            <section ID="LINK_3d87df18-2dda-4d16-b4be-ede5d6584ea0">
               <id root="c6c6c9f9-618b-428a-8310-782642720422"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20250519"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="fluocinolone-acetonide-0-01-percent-topical-oil-ea-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>